Odyssey Therapeutics Reports OD-001 Clinical Trial Data
The Boston-based company released Phase 2a trial results for its oral treatment for moderate-to-severe ulcerative colitis.
Live Poll
Do you trust that pharmaceutical companies are effectively developing new treatments for autoimmune and inflammatory diseases?